Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

90 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
Novo Nordisk hopes to launch experimental obesity drug this decade
RE
Novo Nordisk CEO says innovation in obesity may justify higher price in some segments
RE
Novo's global obesity drug rollout to be dominated by injectable medicines, CEO says
RE
Transcript : Novo Nordisk A/S - Analyst/Investor Day
Novo Nordisk CEO Jorgensen: Demand will outstrip supply for years to come
MT
Novo Nordisk doesn't disappoint
Our Logo
As Lilly competition heats up, Novo CEO details strategy for new Wegovy launches
RE
Transcript : Novo Nordisk A/S, 2023 Earnings Call, Jan 31, 2024
Jorgensen, CEO of Novo Nordisk: €10bn investment to meet demand for its weight loss drugs
MT
Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo
RE
Novo Nordisk sees double-digit FY growth; boosts Wegovy supplies to U.S
RE
Novo Nordisk Begins Gradually Increasing Supply of Blockbuster Weight-Loss Drug Wegovy -- Update
DJ
Novo Nordisk will more than double U.S. lower doses of Wegovy, CEO says
RE
Novo Nordisk sees double-digit FY growth as Q4 profit beats estimate
RE
Novo CEO expects patients to stay on Wegovy longer than older weight loss drugs
RE
Transcript : Novo Nordisk A/S Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM
Novo Nordisk invests $2.3 bln in France to boost obesity drug production
RE
Novo Nordisk Seeks Bolt-On Acquisitions
CI
Drugmaker Novo Nordisk seeks obesity, diabetes 'bolt-on' deals
RE
Novo Nordisk prefers "bolt-on" acquisitions, not large deals, CEO says
RE
EU proposal may accelerate pharma innovation decline, industry group says
RE
Lars Fruergaard Jorgensen, CEO of Novo Nordisk: dose limitation to continue until 2024
MT
Wegovy launch in UK may underline Novo's need to get ahead of Lilly
RE
Novo CEO on Ozempic, Wegovy Demand, Acquisition Strategy
MT
Catalent's Indiana plant to make Novo's Wegovy weight-loss drug-sources
RE
Novo Nordisk A/S : "With obesity, we're dealing with a billion patients worldwide".
Our Logo
Novo Nordisk CEO Lars Fruergaard Jorgensen at Reuters Newsmaker event
RE
Novo says Wegovy drug helps obese people with heart failure in trial
RE
Novo Nordisk tells Europe weight-loss drug will save money as well as lives
RE
Novo Nordisk to launch Wegovy in more countries in 'constrained' manner - CEO
RE
Novo Nordisk CEO 'confident' Catalent will overcome Wegovy production problems
RE
Novo Nordisk to address social inequality in dialogue with healthcare systems -CEO
RE
INTERVIEW - Lars Fruergaard Jorgensen, CEO of Novo Nordisk: Treating obesity will be one of our top healthcare priorities
MT
Novo Nordisk CEO: US limits on weight-loss Wegovy use likely to last into 2024
RE
Europe faces long wait for weight-loss drugs as governments eye costs
RE
Novo Nordisk: Wegovy launch in new markets will be slower than planned due to high demand
RE
Novo Nordisk Reports Surging Demand for Diabetes, Obesity Drugs Ozempic and Wegovy
DJ
Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
Novo Nordisk Sees Strong Demand for Obesity Drug
MT
Transcript : Novo Nordisk A/S, 2022 Earnings Call, Feb 01, 2023
Novo Nordisk to increase manufacturing capacity of weight-loss drugs
RE
Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic
RE
Transcript : Novo Nordisk A/S Presents at JP Morgan EU Healthcare CEO Conference Calls Series 2022, Sep-14-2022 02:00 PM
Obesity drug supply delay not unusual says Novo Nordisk CEO
RE
Transcript : Novo Nordisk A/S, Q2 2022 Earnings Call, Aug 03, 2022
Novo Nordisk 1st Half Profit, Sales Rose on Treatment Demand; Lifts 2022 Guidance
DJ
Novo Nordisk shares fall on Wegovy news despite outlook lift
RE
Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
Transcript : Novo Nordisk A/S, 2021 Earnings Call, Feb 04, 2022
No results for this search
  1. Stock Market
  2. Advanced search
  3. Lars Fruergaard Jorgensen
  4. News